focus -WSS

focus

author：entertainment 2025-09-28 12:09:07 Page View：12447

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here’s where you can read Frank’s work; here’s more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New brain studies show LSD's effects on the brain in full color
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

leisure time

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Why doctors need education on FDA device approval process

AdobeInherfinalpresentationforhealthpolicyclassattheUniversityofChicago,first-yearmedicalstudentRobi

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Humana’s losses in Medicare Advantage tank its stock

Humana’sMedicareAdvantagebusinessisfaringevenworsethanthecompanyletonlastweek.EdReinke/APHumana’sMed

focus

comprehensive

leisure time

Humana’s losses in Medicare Advantage tank its stock